All (17) Journal Article (12) Conference Publication (4) Book Chapter (1)

2025

Conference Publication

Selective inhibition of PI3Kp110a enhances chemotherapy efficacy by suppressing hepatic stellate cell activation in liver cancer

Liang, X., Ruan, Q., Kim, M., Yang, H., Bridle, K. and Crawford, D. (2025). Selective inhibition of PI3Kp110a enhances chemotherapy efficacy by suppressing hepatic stellate cell activation in liver cancer. Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Berlin, Germany, 17 - 21 October 2025. Amsterdam, Netherlands: Elsevier BV. doi: 10.1016/j.annonc.2025.10.194

Selective inhibition of PI3Kp110a enhances chemotherapy efficacy by suppressing hepatic stellate cell activation in liver cancer

2024

Conference Publication

Chemotherapeutic drugs induce hepatic stellate cell activation in hepatocellular carcinoma via ROS-dependent PI3K pathway

Ruan, Qi, Cao, Lu, Yang, Haotian, Burke, Leslie, Bridle, Kim, Crawford, Darrell and Liang, Xiaowen (2024). Chemotherapeutic drugs induce hepatic stellate cell activation in hepatocellular carcinoma via ROS-dependent PI3K pathway. The Liver Meeting, San Diego, CA, United States, 15 - 19 November 2024. Philadelphia, PA, United States: Wolters Kluwer Health.

Chemotherapeutic drugs induce hepatic stellate cell activation in hepatocellular carcinoma via ROS-dependent PI3K pathway

2024

Conference Publication

Therapeutic targeting of a-specific PI3K improves chemotherapy efficacy by inhibiting hepatic stellate cell activation in liver cancer

Ruan, Qi, Cao, Lu, Yang, Haotian, Burke, Leslie, Bridle, Kim, Crawford, Darrell and Liang, Xiaowen (2024). Therapeutic targeting of a-specific PI3K improves chemotherapy efficacy by inhibiting hepatic stellate cell activation in liver cancer. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

Therapeutic targeting of a-specific PI3K improves chemotherapy efficacy by inhibiting hepatic stellate cell activation in liver cancer

2023

Conference Publication

Reactive oxygen species-mediated hepatic stellate cell activation via PI3K in liver cancer

Ruan, Qi, Cao, Lu, Yang, Haotian, Burke, Leslie, Bridle, Kim, Crawford, Darrell and Liang, Xiaowen (2023). Reactive oxygen species-mediated hepatic stellate cell activation via PI3K in liver cancer. EASL Congress 2023, Vienna, Austria, 21 - 24 June 2023. Amsterdam, Netherlands: Elsevier.

Reactive oxygen species-mediated hepatic stellate cell activation via PI3K in liver cancer